Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle

Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6

Daniel Bach, Deborah Naon, Sara Pich, Francesc X. Soriano, Nathalie Vega, Jennifer Rieusset, Martine Laville, Christelle Guillet, Yves Boirie, Harriet Wallberg-Henriksson, Melania Manco, Menotti Calvani, Marco Castagneto, Manuel Palacín, Geltrude Mingrone, Juleen R. Zierath, Hubert Vidal, Antonio Zorzano

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

The primary gene mutated in Charcot-Marie-Tooth type 2A is mitofusin-2 (Mfn2). Mfn2 encodes a mitochondrial protein that participates in the maintenance of the mitochondrial network and that regulates mitochondrial metabolism and intracellular signaling. The potential for regulation of human Mfn2 gene expression in vivo is largely unknown. Based on the presence of mitochondrial dysfunction in insulin-resistant conditions, we have examined whether Mfn2 expression is dysregulated in skeletal muscle from obese or nonobese type 2 diabetic subjects, whether muscle Mfn2 expression is regulated by body weight loss, and the potential regulatory role of tumor necrosis factor (TNF)α or interleukin-6. We show that mRNA concentration of Mfn2 is decreased in skeletal muscle from both male and female obese subjects. Muscle Mfn2 expression was also reduced in lean or in obese type 2 diabetic patients. There was a strong negative correlation between the Mfn2 expression and the BMI in nondiabetic and type 2 diabetic subjects. A positive correlation between the Mfn2 expression and the insulin sensitivity was also detected in nondiabetic and type 2 diabetic subjects. To determine the effect of weight loss on Mfn2 mRNA expression, six morbidly obese subjects were subjected to weight loss by bilio-pancreatic diversion. Mean expression of muscle Mfn2 mRNA increased threefold after reduction in body weight, and a positive correlation between muscle Mfn2 expression and insulin sensitivity was again detected. In vitro experiments revealed an inhibitory effect of TNFα or interleukin-6 on Mfn2 expression in cultured cells. We conclude that body weight loss upregulates the expression of Mfn2 mRNA in skeletal muscle of obese humans, type 2 diabetes downregulates the expression of Mfn2 mRNA in skeletal muscle, Mfn2 expression in skeletal muscle is directly proportional to insulin sensitivity and is inversely proportional to the BMI, TNFα and interleukin-6 downregulate Mfn2 expression and may participate in the dysregulation Mfn2 expression in obesity or type 2 diabetes, and the in vivo modulation of Mfn2 mRNA levels is an additional level of regulation for the control of muscle metabolism and could provide a molecular mechanism for alterations in mitochondrial function in obesity or type 2 diabetes.

Original languageEnglish
Pages (from-to)2685-2693
Number of pages9
JournalDiabetes
Volume54
Issue number9
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Type 2 Diabetes Mellitus
Weight Loss
Interleukin-6
Tooth
Skeletal Muscle
Tumor Necrosis Factor-alpha
Obesity
Messenger RNA
Muscles
Genes
Insulin Resistance
Body Weight
Down-Regulation
Biliopancreatic Diversion
Mitochondrial Proteins
Cultured Cells
Up-Regulation
Maintenance
Insulin
Gene Expression

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle : Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6. / Bach, Daniel; Naon, Deborah; Pich, Sara; Soriano, Francesc X.; Vega, Nathalie; Rieusset, Jennifer; Laville, Martine; Guillet, Christelle; Boirie, Yves; Wallberg-Henriksson, Harriet; Manco, Melania; Calvani, Menotti; Castagneto, Marco; Palacín, Manuel; Mingrone, Geltrude; Zierath, Juleen R.; Vidal, Hubert; Zorzano, Antonio.

In: Diabetes, Vol. 54, No. 9, 09.2005, p. 2685-2693.

Research output: Contribution to journalArticle

Bach, D, Naon, D, Pich, S, Soriano, FX, Vega, N, Rieusset, J, Laville, M, Guillet, C, Boirie, Y, Wallberg-Henriksson, H, Manco, M, Calvani, M, Castagneto, M, Palacín, M, Mingrone, G, Zierath, JR, Vidal, H & Zorzano, A 2005, 'Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6', Diabetes, vol. 54, no. 9, pp. 2685-2693. https://doi.org/10.2337/diabetes.54.9.2685
Bach, Daniel ; Naon, Deborah ; Pich, Sara ; Soriano, Francesc X. ; Vega, Nathalie ; Rieusset, Jennifer ; Laville, Martine ; Guillet, Christelle ; Boirie, Yves ; Wallberg-Henriksson, Harriet ; Manco, Melania ; Calvani, Menotti ; Castagneto, Marco ; Palacín, Manuel ; Mingrone, Geltrude ; Zierath, Juleen R. ; Vidal, Hubert ; Zorzano, Antonio. / Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle : Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6. In: Diabetes. 2005 ; Vol. 54, No. 9. pp. 2685-2693.
@article{c0323bc93b8a438da69f469896736c9a,
title = "Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6",
abstract = "The primary gene mutated in Charcot-Marie-Tooth type 2A is mitofusin-2 (Mfn2). Mfn2 encodes a mitochondrial protein that participates in the maintenance of the mitochondrial network and that regulates mitochondrial metabolism and intracellular signaling. The potential for regulation of human Mfn2 gene expression in vivo is largely unknown. Based on the presence of mitochondrial dysfunction in insulin-resistant conditions, we have examined whether Mfn2 expression is dysregulated in skeletal muscle from obese or nonobese type 2 diabetic subjects, whether muscle Mfn2 expression is regulated by body weight loss, and the potential regulatory role of tumor necrosis factor (TNF)α or interleukin-6. We show that mRNA concentration of Mfn2 is decreased in skeletal muscle from both male and female obese subjects. Muscle Mfn2 expression was also reduced in lean or in obese type 2 diabetic patients. There was a strong negative correlation between the Mfn2 expression and the BMI in nondiabetic and type 2 diabetic subjects. A positive correlation between the Mfn2 expression and the insulin sensitivity was also detected in nondiabetic and type 2 diabetic subjects. To determine the effect of weight loss on Mfn2 mRNA expression, six morbidly obese subjects were subjected to weight loss by bilio-pancreatic diversion. Mean expression of muscle Mfn2 mRNA increased threefold after reduction in body weight, and a positive correlation between muscle Mfn2 expression and insulin sensitivity was again detected. In vitro experiments revealed an inhibitory effect of TNFα or interleukin-6 on Mfn2 expression in cultured cells. We conclude that body weight loss upregulates the expression of Mfn2 mRNA in skeletal muscle of obese humans, type 2 diabetes downregulates the expression of Mfn2 mRNA in skeletal muscle, Mfn2 expression in skeletal muscle is directly proportional to insulin sensitivity and is inversely proportional to the BMI, TNFα and interleukin-6 downregulate Mfn2 expression and may participate in the dysregulation Mfn2 expression in obesity or type 2 diabetes, and the in vivo modulation of Mfn2 mRNA levels is an additional level of regulation for the control of muscle metabolism and could provide a molecular mechanism for alterations in mitochondrial function in obesity or type 2 diabetes.",
author = "Daniel Bach and Deborah Naon and Sara Pich and Soriano, {Francesc X.} and Nathalie Vega and Jennifer Rieusset and Martine Laville and Christelle Guillet and Yves Boirie and Harriet Wallberg-Henriksson and Melania Manco and Menotti Calvani and Marco Castagneto and Manuel Palac{\'i}n and Geltrude Mingrone and Zierath, {Juleen R.} and Hubert Vidal and Antonio Zorzano",
year = "2005",
month = "9",
doi = "10.2337/diabetes.54.9.2685",
language = "English",
volume = "54",
pages = "2685--2693",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "9",

}

TY - JOUR

T1 - Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle

T2 - Effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor α and interleukin-6

AU - Bach, Daniel

AU - Naon, Deborah

AU - Pich, Sara

AU - Soriano, Francesc X.

AU - Vega, Nathalie

AU - Rieusset, Jennifer

AU - Laville, Martine

AU - Guillet, Christelle

AU - Boirie, Yves

AU - Wallberg-Henriksson, Harriet

AU - Manco, Melania

AU - Calvani, Menotti

AU - Castagneto, Marco

AU - Palacín, Manuel

AU - Mingrone, Geltrude

AU - Zierath, Juleen R.

AU - Vidal, Hubert

AU - Zorzano, Antonio

PY - 2005/9

Y1 - 2005/9

N2 - The primary gene mutated in Charcot-Marie-Tooth type 2A is mitofusin-2 (Mfn2). Mfn2 encodes a mitochondrial protein that participates in the maintenance of the mitochondrial network and that regulates mitochondrial metabolism and intracellular signaling. The potential for regulation of human Mfn2 gene expression in vivo is largely unknown. Based on the presence of mitochondrial dysfunction in insulin-resistant conditions, we have examined whether Mfn2 expression is dysregulated in skeletal muscle from obese or nonobese type 2 diabetic subjects, whether muscle Mfn2 expression is regulated by body weight loss, and the potential regulatory role of tumor necrosis factor (TNF)α or interleukin-6. We show that mRNA concentration of Mfn2 is decreased in skeletal muscle from both male and female obese subjects. Muscle Mfn2 expression was also reduced in lean or in obese type 2 diabetic patients. There was a strong negative correlation between the Mfn2 expression and the BMI in nondiabetic and type 2 diabetic subjects. A positive correlation between the Mfn2 expression and the insulin sensitivity was also detected in nondiabetic and type 2 diabetic subjects. To determine the effect of weight loss on Mfn2 mRNA expression, six morbidly obese subjects were subjected to weight loss by bilio-pancreatic diversion. Mean expression of muscle Mfn2 mRNA increased threefold after reduction in body weight, and a positive correlation between muscle Mfn2 expression and insulin sensitivity was again detected. In vitro experiments revealed an inhibitory effect of TNFα or interleukin-6 on Mfn2 expression in cultured cells. We conclude that body weight loss upregulates the expression of Mfn2 mRNA in skeletal muscle of obese humans, type 2 diabetes downregulates the expression of Mfn2 mRNA in skeletal muscle, Mfn2 expression in skeletal muscle is directly proportional to insulin sensitivity and is inversely proportional to the BMI, TNFα and interleukin-6 downregulate Mfn2 expression and may participate in the dysregulation Mfn2 expression in obesity or type 2 diabetes, and the in vivo modulation of Mfn2 mRNA levels is an additional level of regulation for the control of muscle metabolism and could provide a molecular mechanism for alterations in mitochondrial function in obesity or type 2 diabetes.

AB - The primary gene mutated in Charcot-Marie-Tooth type 2A is mitofusin-2 (Mfn2). Mfn2 encodes a mitochondrial protein that participates in the maintenance of the mitochondrial network and that regulates mitochondrial metabolism and intracellular signaling. The potential for regulation of human Mfn2 gene expression in vivo is largely unknown. Based on the presence of mitochondrial dysfunction in insulin-resistant conditions, we have examined whether Mfn2 expression is dysregulated in skeletal muscle from obese or nonobese type 2 diabetic subjects, whether muscle Mfn2 expression is regulated by body weight loss, and the potential regulatory role of tumor necrosis factor (TNF)α or interleukin-6. We show that mRNA concentration of Mfn2 is decreased in skeletal muscle from both male and female obese subjects. Muscle Mfn2 expression was also reduced in lean or in obese type 2 diabetic patients. There was a strong negative correlation between the Mfn2 expression and the BMI in nondiabetic and type 2 diabetic subjects. A positive correlation between the Mfn2 expression and the insulin sensitivity was also detected in nondiabetic and type 2 diabetic subjects. To determine the effect of weight loss on Mfn2 mRNA expression, six morbidly obese subjects were subjected to weight loss by bilio-pancreatic diversion. Mean expression of muscle Mfn2 mRNA increased threefold after reduction in body weight, and a positive correlation between muscle Mfn2 expression and insulin sensitivity was again detected. In vitro experiments revealed an inhibitory effect of TNFα or interleukin-6 on Mfn2 expression in cultured cells. We conclude that body weight loss upregulates the expression of Mfn2 mRNA in skeletal muscle of obese humans, type 2 diabetes downregulates the expression of Mfn2 mRNA in skeletal muscle, Mfn2 expression in skeletal muscle is directly proportional to insulin sensitivity and is inversely proportional to the BMI, TNFα and interleukin-6 downregulate Mfn2 expression and may participate in the dysregulation Mfn2 expression in obesity or type 2 diabetes, and the in vivo modulation of Mfn2 mRNA levels is an additional level of regulation for the control of muscle metabolism and could provide a molecular mechanism for alterations in mitochondrial function in obesity or type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=24144462451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144462451&partnerID=8YFLogxK

U2 - 10.2337/diabetes.54.9.2685

DO - 10.2337/diabetes.54.9.2685

M3 - Article

VL - 54

SP - 2685

EP - 2693

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 9

ER -